SAB Biotherapeutics, Inc. (SABSW)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, SAB Biotherapeutics, Inc. reported revenue of $0, down 100.0% from the prior year. The company was profitable. It held $172.81M in total assets against $21.32M in total liabilities.
Key ratios (FY2025)
8.8%
Return on equity
-100.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1.32M | $2.24M | $23.90M | $60.88M | $55.24M | — |
| Operating Income | -$48.95M | -$42.91M | -$38.08M | -$28.92M | -$13.39M | $20.56M | — |
| Net Income | $13.27M | -$34.11M | -$42.19M | -$18.74M | -$17.14M | $20.12M | — |
| EPS (Diluted) | $-0.79 | $-3.68 | $-7.64 | $-4.31 | $-0.63 | $0.74 | — |
| Total Assets | $172.81M | $44.20M | $83.94M | $50.90M | $81.14M | $56.54M | — |
| Total Liabilities | $21.32M | $18.23M | $26.64M | $19.85M | $42.59M | $17.53M | — |
| Shareholders' Equity | $151.49M | $25.97M | $57.30M | $31.06M | $38.55M | $39.01M | $7.69M |
| Cash & Equivalents | $10.50M | $8.90M | $56.57M | $15.05M | $33.21M | $12.61M | — |
| Operating Cash Flow | -$44.78M | -$34.29M | -$25.12M | -$23.46M | $1.99M | $10.00M | — |
| Capital Expenditures | $933.2K | $337.3K | $197.2K | $2.17M | $10.94M | $12.73M | — |
| Shares Outstanding | 47.61M | 9.29M | 9.23M | 5.04M | 43.49M | 25.97M | — |